🔗 Share this article

A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.

Investigational Drug Acquiring Popularity Online

The experimental drug, which remains in research studies, is being advertised by online personalities for its alleged weight-reducing properties. Viewers are encouraged to contact these profiles directly for supplier links, while also obtaining discount codes.

Active Commerce on Messaging Platforms

Separately, a robust trade exists on Telegram, where groups with thousands of participants share “before and after” photos, injection guides and assertions of next-day UK delivery. Vendors promote the substance there before directing buyers to other platforms for transactions.

Understanding Retatrutide

This medication is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.

Healthcare Experts Voice Concerns

Nevertheless, physicians and chemists have cautions that the sale of what is still an unapproved drug in the UK is a cause for concern and could result in users injecting substances of uncertain source.

Several professionals stated the demand for retatrutide could be linked to the rising price of licensed weight loss treatments such as Mounjaro.

Regulatory Position and Enforcement

Marketing retatrutide on social media or messaging apps is illegal in the UK, as it is an unlicensed medication that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to circumvent the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still violate pharmaceutical, marketing, and customer laws, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Content Removal

Based on the social media company, the platform has taken down problematic material and banned related hashtags and search suggestions. The organization said it was committed to maintaining the platform secure and allocating resources in enhancing compliance measures.

Online Marketplace Operations

Investigations also discovered communities with up to 9,000 members selling the experimental drug using Telegram's built-in search feature, which operates like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, populated with images of weight loss, glowing testimonials and detailed guides for mixing or injecting at home.

Within moments of entering one group, a vendor shared WhatsApp details, where most purchases occur. The vendor provided an guidebook and guaranteed shipping within two days. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another shared a image of a alleged testing documentation. None asked about body mass, medical conditions or past usage.

Product Details and Costs

Within these groups, posts show dark colored parcels with postal service labels, stating to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at home with sterile water, or ready-to-use injectors usually priced at 160 pounds for 20mg. When questioned how much time a injector should be used, vendors give conflicting responses varying between a several days to “depends on your body”.

Platform Moderation and Security Actions

A spokesperson for the messaging service stated it regularly monitored dangerous content on its service including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering substances they cannot confirm. Although the science behind retatrutide is valid, these digital products may not include what they advertise,” stated a pharmacy expert, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in interest to current price rises for authorized slimming drugs such as Mounjaro. “With costs rising, patients are turning to online platforms. But fake treatments are extremely risky. You cannot know what’s inside or whether the environment they were made in was sterile,” she explained.

Her staff has already seen patients harmed by self-injection from unverified sources. “We understand the frustration, but buying from messaging apps or communication platforms is gambling with your health,” stated Wyllie. “These substances could be contaminated or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any regulatory agency globally. “Consequently at this time no one can market [it] for personal consumption,” they explained, noting that any item “falsely representing itself as a company investigational substance not yet authorized … may subject users to potentially significant health risks”.